BioCryst Statistics
BioCryst (BO1) Stock Statistics & Valuation Metrics
Total Valuation
BioCryst has a market cap or net worth of EUR 1.73B. The enterprise value is EUR 2.68B.
- Market Cap
- EUR 1.73B
- Enterprise Value
- EUR 2.68B
Share Statistics
BioCryst has 257,299,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 257,299,260
- Owned by Insiders
- 1.46%
- Owned by Institutions
- 41.04%
Financial Efficiency
BioCryst’s return on equity (ROE) is -2.21 and return on invested capital (ROIC) is 105.24%.
- Return on Equity (ROE)
- -2.21
- Return on Assets (ROA)
- 0.51
- Return on Invested Capital (ROIC)
- 105.24%
- Return on Capital Employed (ROCE)
- 1.07
- Revenue Per Employee
- 2.01M
- Profits Per Employee
- 606.58K
- Employee Count
- 435
- Asset Turnover
- 1.70
- Inventory Turnover
- 3.53
Valuation Ratios
The current PE Ratio of BioCryst is -5.58. BioCryst’s PEG ratio is 0.00.
- PE Ratio
- -5.58
- PS Ratio
- 2.00
- PB Ratio
- -4.84
- Price to FCF
- 5.50
- Price to Operating Cash Flow
- 5.48
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, BioCryst had revenue of 874.84M and earned 263.86M in profits. Earnings per share was 1.26.
- Revenue
- 874.84M
- Gross Profit
- 855.76M
- Operating Income
- 340.99M
- Pretax Income
- 267.39M
- Net Income
- 263.86M
- EBITDA
- 347.65M
- Earnings Per Share (EPS)
- 1.26
Cash Flow
In the last 12 months, operating cash flow was 351.23M and capital expenditures -1.65M, giving a free cash flow of 349.58M billion.
- Operating Cash Flow
- 351.23M
- Free Cash Flow
- 349.58M
- Free Cash Flow per Share
- 1.37
Dividends & Yields
BioCryst pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 18.23%
- Earnings Yield
- -18.75%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- 11.90%
- 50-Day Moving Average
- 7.42
- 200-Day Moving Average
- 7.60
- Relative Strength Index (RSI)
- 40.24
- Average Volume (3m)
- 778
Important Dates
BioCryst upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
BioCryst as a current ratio of 2.06, with Debt / Equity ratio of -368.33%
- Current Ratio
- 2.06
- Quick Ratio
- 2.03
- Debt to Market Cap
- 0.26
- Net Debt to EBITDA
- 1.00
- Interest Coverage Ratio
- 4.32
Taxes
In the past 12 months, BioCryst has paid 3.53M in taxes.
- Income Tax
- 3.53M
- Effective Tax Rate
- 0.01
Enterprise Valuation
BioCryst EV to EBITDA ratio is -9.29, with an EV/FCF ratio of 7.58.
- EV to Sales
- 2.76
- EV to EBITDA
- -9.29
- EV to Free Cash Flow
- 7.58
- EV to Operating Cash Flow
- 7.54
Balance Sheet
BioCryst has EUR 375.00M in cash and marketable securities with EUR 828.20M in debt, giving a net cash position of -EUR 453.20M billion.
- Cash & Marketable Securities
- EUR 375.00M
- Total Debt
- EUR 828.20M
- Net Cash
- -EUR 453.20M
- Net Cash Per Share
- -EUR 1.76
- Tangible Book Value Per Share
- -EUR 1.55
Margins
Gross margin is 25.28%, with operating margin of -30.10%, and net profit margin of -37.41%.
- Gross Margin
- 25.28%
- Operating Margin
- -30.10%
- Pretax Margin
- -36.89%
- Net Profit Margin
- -37.41%
- EBITDA Margin
- -29.65%
- EBIT Margin
- -30.24%
Analyst Forecast
The average price target for BioCryst is EUR 15.16, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 15.16
- Price Target Upside
- 124.07% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 52.63%
- EPS Growth Forecast
- -2345.22%
Scores
- Smart Score
- 9
- AI Score
- ―
